ResearcherActive in the last 2 years

Kathlen Oliveira Martins Tiede

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2369-4450; OpenAlex author ID A5096085285. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. Co-author DOI 10.1038/s41598-026-40757-3 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mitesh J. Borad · 1 shared paper, 2026 · strength 0.30
- Paper Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. DOI 10.1038/s41598-026-40757-3 ↗
Mohamad Bassam Sonbol · 1 shared paper, 2026 · strength 0.30
- Paper Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. DOI 10.1038/s41598-026-40757-3 ↗
Fernando Moura · 1 shared paper, 2026 · strength 0.30
- Paper Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. DOI 10.1038/s41598-026-40757-3 ↗
Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.30
- Paper Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. DOI 10.1038/s41598-026-40757-3 ↗
Pedro Luiz Serrano Usón · 1 shared paper, 2026 · strength 0.30
- Paper Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. DOI 10.1038/s41598-026-40757-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.